ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

On August9, 2017, ABIOMED, Inc. (the “Company”) held its Annual Meeting. The holders of 41,347,067 shares of common stock were present or represented by a proxy at the meeting. Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter as reported by the inspector of elections.

Proposal One: Election of Directors

At the Annual Meeting, the Company’s stockholders elected each of Dorothy E. Puhy, Paul G. Thomas and Christopher D. Van Gorder as a member of the Company’s board of directors as a ClassI director to serve a three-year term expiring at the 2020 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, with the votes cast as follows, in addition to 8,156,512 Broker Non-Votes:

Proposal Two: Advisory Vote on Executive Compensation

At the Annual Meeting, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement filed in connection with the Annual Meeting, with the votes cast as follows:

Proposal Three: Advisory Vote on Frequency of Future Advisory Vote on Executive Compensation

At the Annual Meeting, the Company’s stockholders approved, on an advisory basis, that the frequency of future advisory votes on compensation paid to the named executive officers of the Company be every year, with the votes cast as follows:

After taking into consideration the foregoing results, the Board has determined that the Company will hold such future advisory votes every year until the next vote on the frequency of such votes is held, which will be no later than the annual meeting of stockholders in 2023.

Proposal Four: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

At the Annual Meeting, the Company’s stockholders ratified the appointment of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending March31, 2018, with the votes cast as follows:

About ABIOMED, Inc. (NASDAQ:ABMD)

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.